GSK Plc highlighted progress with its vaccine portfolio in presenting its first quarter financial results on 26 April. Shingrix, its vaccine for shingles, produced sales of £833 million during the quarter or 12% of total group turnover. This exceeded total sales from respiratory and immunology products and was well above revenue from oncology medicines.
